CRISPR-Cas9 modified bacteriophage for treatment of Staphylococcus aureus induced osteomyelitis and soft tissue infection
L. K. Horstemeyer, J. Park, E. A. Swanson, M. C. Beard, E. M. McCabe, A. S. Rourke, K. S. Seo, A. K. Olivier, L. B. Priddy
This study evaluates CRISPR-Cas9 modified bacteriophages for treating Staphylococcus aureus infections in vitro and in a rat osteomyelitis model, showing efficacy against biofilm and soft tissue infection.
bioRxiv · Jul 18, 2019Bioengineering